Motor Cortex Stimulation for Chronic Neuropathic Pain

This study is currently recruiting participants.
Verified October 2012 by St. Jude Medical
Sponsor:
Information provided by (Responsible Party):
St. Jude Medical
ClinicalTrials.gov Identifier:
NCT01554332
First received: January 13, 2012
Last updated: October 9, 2012
Last verified: October 2012

January 13, 2012
October 9, 2012
October 2012
September 2014   (final data collection date for primary outcome measure)
Visual Analog Scale (VAS) [ Time Frame: Approximately 7 months ] [ Designated as safety issue: No ]
The primary analysis of effectiveness is based on the mean differences in changes from the period-specific baseline in VAS scores when patients are receiving 3 month of active vs. 3 months of sham stimulation on a double-blinded fashion.
Same as current
Complete list of historical versions of study NCT01554332 on ClinicalTrials.gov Archive Site
  • Visual Analog Scale, responder [ Time Frame: Participants will be followed for approximatley 18 months ] [ Designated as safety issue: No ]
    defined as a ≥30% or 2 points reduction from baseline in VAS scores
  • Neuropathic Pain Symptom Inventory (NPSI) [ Time Frame: Participants will be followed for approximatley 18 months ] [ Designated as safety issue: No ]
  • Brief Pain Inventory (BPI) [ Time Frame: Participants will be followed for approximatley 18 months ] [ Designated as safety issue: No ]
  • Short Form of the McGill Pain Questionnaire(SF-MPQ) [ Time Frame: Participants will be followed for approximatley 18 months ] [ Designated as safety issue: No ]
  • Sickness Impact Profile (SIP) [ Time Frame: Participants will be followed for approximatley 18 months ] [ Designated as safety issue: No ]
  • Medication Quantification Scale (MQS) [ Time Frame: Participants will be followed for approximatley 18 months ] [ Designated as safety issue: No ]
  • SF-36 Health Survey and safety [ Time Frame: Participants will be followed for approximatley 18 months ] [ Designated as safety issue: No ]
  • Pain Catastrophizing Scale (PCS) [ Time Frame: Participants will be followed for approximatley 18 months ] [ Designated as safety issue: No ]
  • Global Impression of Change (patient and evaluator's version) [ Time Frame: Participants will be followed for approximatley 18 months ] [ Designated as safety issue: No ]
  • Device related Adverse Events [ Time Frame: Participants will be followed for approximatley 18 months ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Motor Cortex Stimulation for Chronic Neuropathic Pain
A Clinical Evaluation for the Management of Patients With Chronic Neuropathic Pain With Cortical Stimulation

The purpose of this study is to evaluate the efficacy of cortical stimulation (CS) as an adjunctive treatment for chronic neuropathic pain.

Prospective, controlled, double blind, randomized, crossover study with endpoint evaluations at the end of each 3-month treatment period.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Neuropathic Pain
  • Facial Pain
  • Post-stroke Pain
  • Brachial Plexus Avulsion
  • Phantom Limb Pain of the Upper Extremities
Device: Motor Cortex Stimulation using SJM EonC Stimulator
Patients will be randomized to receive either active stimulation the first 3 months followed by a one-month washout, followed by Sham Stimulation the next 3 months, vs. the reverse order of treatment, followed by single blind stimulation, and an open label phase.
  • Active Comparator: Active stimulation
    Intervention: Device: Motor Cortex Stimulation using SJM EonC Stimulator
  • Sham Comparator: Sham stimulation
    Intervention: Device: Motor Cortex Stimulation using SJM EonC Stimulator
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
44
September 2015
September 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Men and women (non-pregnant) age 21-70 years;
  • Able to give informed consent in accordance with institutional policies;
  • Diagnosis of chronic neuropathic pain according to the DN4 Neuropathic Pain Diagnosis scale (score ≥ 4).
  • Documented pain for at least 12 months;
  • Documented previous or current treatment for neuropathic pain with medications from at least two of the following groups at adequate doses: antidepressants, anticonvulsants, and/or gabapentinoids;
  • VAS scores of at least 6 during baselines #1 and 2.
  • Documented clinical diagnosis of neuropathic pain associated with one of the following conditions: facial pain, post-stroke pain, brachial plexus avulsion, or phantom limb pain of the upper extremities.
  • In the group with post-stroke pain, only patients with predominant face and upper extremity pain will be included. This will be defined as a difference of ≥ 30% or ≥ 2 points in VAS scores between these regions and lower extremity (in patients who also have pain in the leg).
  • No change in current neuropathic pain medication regimen for at least 4 weeks prior to study enrollment.
  • Able to comply with all testing and follow-up requirements as defined by the study protocol.
  • Must be determined medically stable by surgeon to undergo cortical stimulation surgical procedure.

Exclusion Criteria:

  • Alcohol, medication, or illegal substance dependence or abuse within last 12 months;
  • Trigeminal neuralgia or atypical facial pain.
  • Post-stroke pain predominantly in the lower extremity.
  • Advanced cardiovascular disease which renders anesthesia and surgery as unsafe as determined by neurosurgeon;
  • Clinically relevant abnormality (e.g. tumor) on study MRI;
  • Has cardiac pacemaker/defibrillator or other implanted active stimulator;
  • Has a medical condition requiring a repetitive MRI body scan;
  • Requires chemotherapy for the treatment of malignancy or requiring chronic oral or intravenous, immunosuppressive, or steroid therapy;
  • Is unable to comply with study visit schedule and timeline;
  • Past ablative or relevant intracranial surgery;
  • A female lactating or of child bearing potential, with a positive pregnancy test or not using adequate contraception;
  • Other medical conditions likely to require hospitalization within the next year.
Both
21 Years to 70 Years
No
Contact: Manoel Jacobsen Teixeira, MD (11)3069-6440 manoeljteixeira@aol.com
Brazil
 
NCT01554332
C-11-13
No
St. Jude Medical
St. Jude Medical
Not Provided
Study Director: DeLea Peichel St. Jude Medical Neuromodulation Division
St. Jude Medical
October 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP